Top 10 Companies in the (S)-3,4-Dihydroxybutyronitrile (CAS 126577-60-4) Market (2026): Market Leaders Powering Global Synthesis

MARKET INSIGHTS

The Global (S)-3,4-Dihydroxybutyronitrile (CAS 126577-60-4) market size was valued at USD 18.4 million in 2025. The market is projected to grow from USD 19.7 million in 2026 to USD 34.2 million by 2034, exhibiting a CAGR of 7.1% during the forecast period.

(S)-3,4-Dihydroxybutyronitrile is a chiral building block and specialty fine chemical characterized by its hydroxyl and nitrile functional groups. It is widely recognized for its role as a versatile intermediate in asymmetric synthesis, particularly in the production of pharmaceuticals, agrochemicals, and other high‑value chemical compounds. Its defined stereochemistry makes it especially valuable in processes where enantiomeric purity is critical to the efficacy and safety of end products.

The market is steadily gaining traction, driven by growing demand for enantiopure intermediates in pharmaceutical synthesis and increasing investment in chiral chemistry research. The expansion of contract research and manufacturing organizations globally has broadened the compound’s commercial applicability. Key suppliers operating in this space include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Combi‑Blocks, among other fine chemical manufacturers offering this compound across research and industrial‑scale applications.

(S)-3,4-Dihydroxybutyronitrile (CAS 126577-60-4) Market – View in Detailed Research Report

Top 10 Companies

1. Hangzhou Hairui Chemical Co., Ltd.

   Headquarters: Hangzhou, China
   Key Offering: High‑purity (S)-3,4‑Dihydroxybutyronitrile for API synthesis

   Hangzhou Hairui has developed a proprietary two‑step asymmetric synthesis that delivers >99% enantiomeric excess while maintaining cost‑efficiency. The company’s integrated supply chain, spanning raw‑material sourcing to final packaging, allows rapid turnaround for pharmaceutical clients.

   Sustainability Initiatives:

   • Implementation of closed‑loop solvent recovery systems reducing waste by 30%
   • Use of renewable feedstock in the nitrile precursor stage
   • Carbon‑neutral production target by 2030

2. Shanghai Sinofluoro Scientific Co., Ltd.

   Headquarters: Shanghai, China
   Key Offering: Enantiopure intermediates for agrochemical and nutraceutical applications

   Sinofluoro’s process leverages biocatalytic resolution, enabling scalable production of (S)-3,4‑Dihydroxybutyronitrile with minimal energy input. The firm’s strong R&D pipeline includes derivatives for next‑generation crop protection agents.

   Sustainability Initiatives:

   • Zero‑liquid‑discharge (ZLD) system for waste minimization
   • Partnerships with local universities for green chemistry research
   • Energy‑efficient continuous flow reactors

3. Combi‑Blocks Inc.

   Headquarters: Irvine, California, USA
   Key Offering: Custom chiral building blocks for drug discovery

   Combi‑Blocks specializes in rapid, modular synthesis of chiral intermediates. Its platform supports both batch and continuous processes, enabling quick turnaround for pharmaceutical R&D labs.

   Sustainability Initiatives:

   • Adoption of bio‑based solvents across all product lines
   • Life‑cycle assessment (LCA) integration for every new compound
   • Investment in renewable electricity for manufacturing sites

4. TCI Chemicals (Tokyo Chemical Industry Co., Ltd.)

   Headquarters: Tokyo, Japan
   Key Offering: High‑purity (S)-3,4‑Dihydroxybutyronitrile for API and specialty chemical use

   TCI’s multi‑product facilities combine traditional synthesis with modern biocatalytic techniques, ensuring consistent quality and scalable production. The company serves a broad portfolio of pharmaceutical manufacturers worldwide.

   Sustainability Initiatives:

   • ISO 14001 certified manufacturing sites
   • Reduction of volatile organic compound (VOC) emissions by 25%
   • Commitment to 100% renewable energy by 2035

5. Sigma‑Aldrich (Merck KGaA)

   Headquarters: Darmstadt, Germany
   Key Offering: Research‑grade and GMP‑grade (S)-3,4‑Dihydroxybutyronitrile

   Sigma‑Aldrich provides both research‑grade and GMP‑qualified lots, supporting early‑stage discovery and late‑stage manufacturing. Its robust quality management system ensures compliance with global regulatory frameworks.

   Sustainability Initiatives:

   • Carbon‑footprint reduction program across all production lines
   • Water‑recycling infrastructure in key facilities
   • Participation in the European Biocatalysis Consortium

6. Nanjing Chemlin Chemical Industry Co., Ltd.

   Headquarters: Nanjing, China
   Key Offering: Custom chiral intermediates for pharmaceutical and agrochemical sectors

   Chemlin’s process integrates asymmetric hydrogenation with enzyme‑mediated resolution, offering high enantioselectivity and scalability. The firm has recently expanded its capacity to meet rising demand from CDMO partners.

   Sustainability Initiatives:

   • Implementation of green solvent protocols across all lines
   • On‑site renewable energy generation (solar panels)
   • Zero‑waste policy for chemical by‑products

7. Fluorochem Ltd.

   Headquarters: Birmingham, United Kingdom
   Key Offering: High‑purity (S)-3,4‑Dihydroxybutyronitrile for academic and industrial use

   Fluorochem’s advanced chiral resolution methods allow rapid production of the (S) enantiomer with minimal racemization. The company maintains a strong presence in the UK’s pharmaceutical research community.

   Sustainability Initiatives:

   • Use of recycled feedstock in the nitrile synthesis step
   • Reduction of packaging waste via biodegradable materials
   • Participation in the UK Green Chemistry Initiative

8. Zhengzhou Alfa Chemical Co., Ltd.

   Headquarters: Zhengzhou, China
   Key Offering: GMP‑grade (S)-3,4‑Dihydroxybutyronitrile for API manufacturing

   Alfa’s state‑of‑the‑art facilities use continuous flow technology to achieve high throughput while maintaining stringent purity standards. The company’s focus on regulatory compliance positions it as a preferred supplier for global pharma clients.

   Sustainability Initiatives:

   • Energy‑efficient process design reducing CO₂ emissions by 18%
   • Water‑recycling systems achieving >90% reuse
   • Strategic partnership with local universities for sustainable process development

9. Shanghai Chem Ltd.

   Headquarters: Shanghai, China
   Key Offering: Research‑grade (S)-3,4‑Dihydroxybutyronitrile for academic and early‑stage drug discovery

   Shanghai Chem’s flexible production platform supports rapid scale‑up for both research and industrial needs. The firm emphasizes rigorous analytical validation to meet the demands of high‑purity synthesis.

   Sustainability Initiatives:

   • Adoption of green chemistry principles in all synthetic routes
   • Implementation of waste‑minimization protocols across the supply chain
   • Carbon‑neutral goal for 2035

10. VWR International

    Headquarters: North Carolina, USA
    Key Offering: Commercial‑grade (S)-3,4‑Dihydroxybutyronitrile for pharmaceutical and fine‑chemical applications

    VWR’s global distribution network ensures timely delivery of high‑purity intermediates to laboratories and manufacturing sites worldwide. The company’s focus on quality assurance aligns with the strict requirements of the pharmaceutical industry.

    Sustainability Initiatives:

    • Reduction of single‑use plastic packaging by 35%
    • Investment in renewable energy across manufacturing facilities
    • Collaboration with suppliers to improve supply‑chain sustainability metrics

11. Alfa Aesar (Merck KGaA)

    Headquarters: Milwaukee, Wisconsin, USA
    Key Offering: Research‑grade (S)-3,4‑Dihydroxybutyronitrile with detailed analytical data

    Alfa Aesar’s catalog includes comprehensive certificates of analysis, ensuring that end users can validate purity and stereochemistry before integration into synthesis workflows.

    Sustainability Initiatives:

    • Implementation of closed‑loop solvent recovery across all production lines
    • Commitment to reducing greenhouse gas emissions by 20% by 2030
    • Active participation in the Sustainable Development Goals (SDG) reporting framework

Download FREE Sample Report: (S)-3,4-Dihydroxybutyronitrile (CAS 126577-60-4) Market – View in Detailed Research Report

Get Full Report: (S)-3,4-Dihydroxybutyronitrile (CAS 126577-60-4) Market – View in Detailed Research Report

Market Outlook

Over the next decade, the (S)-3,4‑Dihydroxybutyronitrile market will be shaped by the convergence of two forces: the continued expansion of chiral drug development and the growing adoption of green chemistry in fine‑chemical synthesis. Pharmaceutical companies seeking single‑enantiomer APIs will increasingly turn to high‑purity intermediates, while regulators will enforce stricter purity thresholds. Concurrently, the industry’s shift toward biocatalytic and continuous‑flow processes will reduce production costs and environmental footprints, creating a virtuous cycle that drives adoption.

Future Trends

• Biocatalytic production of (S)-3,4‑Dihydroxybutyronitrile using engineered enzymes will become the preferred route, offering superior enantioselectivity and lower energy consumption.
• Integration of digital twins and AI‑driven process optimization will enable real‑time control of stereochemical purity, reducing batch‑to‑batch variability.
• Expansion of CDMO capabilities in Asia‑Pacific, especially in India and China, will increase demand for chiral intermediates across a broader range of therapeutic classes.
• Regulatory frameworks such as REACH and FDA’s guidance on chiral purity will push the market toward higher enantiomeric excess standards, elevating the premium segment.
• Emerging agrochemical applications will open new verticals, as chiral active ingredients are increasingly favored for their selective mode of action and reduced environmental impact.